E.C. Eringa

Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026). Heart failure with a preserved ejection fraction: synergy between cardiac and extracardiac mechanisms and effects of novel therapies. Heart Failure Reviews, 31(1), Article 108. https://doi.org/10.1007/s10741-026-10671-x

Namba, H. F., de Jong, E. A. M., Boerhout, C. K. M., Mechroubi, A., Nijkamp, T., Damman, P., Dimitriu-Leen, A. C., Meuwissen, M., Heestermans, T. A. C. M., den Haan, M. C., Beijk, M. A. M., Vos, N. S., Escaned, J., den Ruijter, H. M., Appelman, Y., Eringa, E. C., Delewi, R., Piek, J. J., & van de Hoef, T. P. (2026). Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study. American Heart Journal, 299, Article 107451. https://doi.org/10.1016/j.ahj.2026.107451

Kopytina, V., Marchant, V., Rodrigues-Diez, R., Pascual-Anton, L., Toggweiler, N., Strahl, L., Kane, J., Tejera-Munoz, A., Cortes, M., Sucunza, D., Vaquero, J. J., Vervloet, M., Piecha, D., Eringa, E. C., Ruiz-Ortega, M., Lopez-Cabrera, M., & Gonzalez-Mateo, G. T. (2026). Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions. Nephrology Dialysis Transplantation, 41(6), 1147-1160. Article gfaf249. https://doi.org/10.1093/ndt/gfaf249

Roy, S., Kane, J., Grigorieva, I., Roche-Dugmore, D., Moore, S., Steadman, R., Raby, A.-C., Jakulj, L., Schurgers, L., Lutgens, E., Eringa, E. C., Vervloet, M., Fraser, D., & Meran, S. (2026). Hyaluronan Regulates Vascular Smooth Muscle Cell Osteogenic Differentiation and Vascular Calcification. Biomolecules, 16(5), Article 729. https://doi.org/10.3390/biom16050729

van de Bovenkamp, A. A., Nassiri, S., de Man, F. S., Oosterveer, F. P. T., Mourmans, S. G. J., van Raalte, D. H., Dijkmans, P. A., van Heerebeek, L., van Empel, V. P. M., Eringa, E. C., Bakermans, A. J., & Handoko, M. L. (2026). Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomized clinical trial. European journal of heart failure. Advance online publication. https://doi.org/10.1093/ejhf/xuag162

Meulendijks, E. R., Fabrizi, B., Bruns, S., Eringa, E. C., Hoebe, R., van den Boogert, T., Wesselink, R., Al-Shama, R. F. M., de Vries, T. A. C., Ernault, A. C., Niessen, H. W. M., van Boven, W. J. P., Driessen, A. H. G., Zbairi, I., Zappala, P., Dey, D., Isgum, I., Planken, R. N., Krul, S. P. J., & de Groot, J. R. (2025). Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation. Cardiovascular Diabetology, 25(1), Article 82. https://doi.org/10.1186/s12933-025-02985-1

Nassiri, S., Voordes, G. H. D., van Heerebeek, L., van Raalte, D. H., Verhaar, M. C., Touw, D. J., Krebber, M. M., Duncker, D. J., Eringa, E. C., Handoko, M. L., Voors, A. A., & RECONNEXT Consortium (2025). Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial. European journal of heart failure, 27(12), 3304-3311. https://doi.org/10.1002/ejhf.3711

Ramos, K. S., Nassiri, S., Wijdeveld, L. F. J., van der Palen, R. L., Kuipers, M. F., Hills, M. T., Slijkerman, P., van Raalte, D. H., Handoko, M. L., de Groot, N. M. S., Grewal, N., Klautz, R. J. M., Eringa, E. C., & Brundel, B. J. J. M. (2025). Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY). Cardiovascular Drugs and Therapy, 39(6), 1589-1595. https://doi.org/10.1007/s10557-025-07693-2

Janssen-Telders, C., Eringa, E. C., de Groot, J. R., de Man, F. S., & Handoko, M. L. (2025). The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction. Cardiovascular Research, 121(6), 860-870. https://doi.org/10.1093/cvr/cvaf056

Suthahar, N., Mourmans, S. G. J., Achten, A., Aboumsallem, J. P., Meijers, W. C., Bomer, N., Kardys, I., Gansevoort, R. T., Bakker, S. J. L., Weerts, J., Eringa, E. C., Damman, K., van Empel, V., & de Boer, R. A. (2025). Peroxiredoxin-4, a marker of systemic oxidative stress, is associated with incident heart failure. European journal of heart failure, 27(5), 905-911. Article 3653. https://doi.org/10.1002/ejhf.3653